Successful Treatment of Chronic Myeloproliferative Disease-Unclassifiable (CMPD-U) With No Chromosomal Abnormalities by Imatinib Mesylate

Internal Medicine - Japan
doi 10.2169/internalmedicine.47.0714
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Japanese Society of Internal Medicine

Related search

Chromosomal Abnormalities in Philadelphia Chromosome Negative Metaphases Appearing During Imatinib Mesylate Therapy in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase

Blood
BiochemistryImmunologyCell BiologyHematology
2007English

Epstein-Barr Virus-Associated Lymphoproliferative Disease During Imatinib Mesylate Treatment for Chronic Myeloid Leukemia

Haematologica
Hematology
2019English

Imatinib Mesylate for the Treatment of Steroid-Refractory Sclerotic-Type Cutaneous Chronic Graft-Versus-Host Disease

Biology of Blood and Marrow Transplantation
TransplantationHematology
2015English

Development of Multiple Myeloma in a Patient With Chronic Myeloid Leukemia After Treatment With Imatinib Mesylate

Oncologist
Cancer ResearchMedicineOncology
2005English

Phase II Pilot Study of Imatinib Mesylate for the Treatment of Severe Sclerotic Skin Chronic Graft Versus Host Disease (ScGVHD)

Biology of Blood and Marrow Transplantation
TransplantationHematology
2012English

Imatinib Mesylate Suppresses Cytokine Synthesis by Activated CD4 T Cells of Patients With Chronic Myelogenous Leukemia

Leukemia
Cancer ResearchOncologyAnesthesiologyPain MedicineHematology
2005English

Micro-Rna Response to Imatinib Mesylate in Patients With Chronic Myeloid Leukemia

Haematologica
Hematology
2010English

Imatinib Mesylate Resistance Through BCR-ABL Independence in Chronic Myelogenous Leukemia

Cancer Research
Cancer ResearchOncology
2004English

Reduced-Intensity Allogeneic Transplantation Combined With Imatinib Mesylate for Chronic Myeloid Leukemia in First Chronic Phase

Leukemia
Cancer ResearchOncologyAnesthesiologyPain MedicineHematology
2009English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy